Imatinib Sandoz (Imatinib Mesilate)

Imatinib mesilate blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of these enzymes, the drug stops downstream signalling that drives malignant cell proliferation and survival, leading to tumour cell death or growth arrest.

The prescribed dose of Imatinib Sandoz is determined by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

Imatinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should only be used during pregnancy if the potential benefit justifies the risk. Breastfeeding is not recommended while on therapy because the drug is excreted in milk. Discuss alternatives with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for many patients. Newer agents such as dasatinib or nilotinib have higher potency and may be used when resistance or intolerance to Imatinib occurs. Choice of therapy depends on disease characteristics, mutation profile and individual patient factors.

Store Imatinib Sandoz tablets at ambient temperature, below 25 °C, in the original container. Protect the product from moisture, direct sunlight and excessive heat to maintain stability throughout its shelf life.

Imatinib Sandoz is taken orally as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious adverse events include hepatotoxicity, severe neutropenia, and cardiac failure. Patients should be monitored regularly for liver enzyme elevations, blood‑cell counts and signs of heart dysfunction. Prompt medical attention is required if any of these serious symptoms develop.

Imatinib Sandoz is contraindicated in individuals with known hypersensitivity to imatinib mesilate or any of the tablet excipients. It should also be avoided in pregnant women unless absolutely necessary, and in patients with severe hepatic impairment without careful medical supervision.